Immunovant IMVT
NASDAQ IMVT
$33.46 -0.03 (-0.09%)
At close: Sep 29, 2026 · 4:00 PM EDT

Immunovant (IMVT) Operating Income (2019)

Updated

Immunovant's Operating Income came in at -$512,549 for fiscal Q2 2020 (quarter ended Sep 30, 2019).

Analysis

Immunovant (IMVT) Operating Income (2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 7.14 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 6.43 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn -584.00 Mn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 4.75 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 3.16 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 3.51 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -10.39 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 4.27 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 1.25 Bn
10 Immunovant 6.91 Bn 6.91 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2019 -419,757.00
Jun 30, 2019 -92,342.00
API Access

Immunovant Operating Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-income&ticker=IMVT&period=max&api_key=YOUR_API_KEY